CDC: Fentanyl drastically impacting the HIV outbreak in Merrimack Valley

CDC: Fentanyl drastically impacting the HIV outbreak in Merrimack Valley

0 CDC: Fentanyl drastically impacting the HIV outbreak in Merrimack Valley LAWRENCE, Mass. – The number of HIV infections is rising in Lowell and Lawrence, with 68 new infections reported since the start of 2017. The main cause? Drug users sharing syringes or using dirty needles.  The opioid related HIV outbreak in the Merrimack Valley […]

Herpes Vaccines Flop. What About Drugs? Pritelivir: A Page From The AIDS Playbook

Herpes Vaccines Flop. What About Drugs? Pritelivir: A Page From The AIDS Playbook

Based on the recent demise of experimental vaccines from Genocea and Vical the prospects for a therapeutic vaccine for genital herpes look mighty bleak at this time. So, for most patients who need treatment valacyclovir (Valtrex) is the only choice (1,2). It works well for most people, but not for everyone. DRUGS VS. VACCINES FOR TREATMENT OF […]

Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

GlaxoSmithKline plc’s (GSK – Free Report) HIV company, ViiV Healthcare announced that the two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine (Epivir) met the primary endpoint. The two phase III studies, GEMINI-1 and GEMINI-2, evaluated the two-drug regimen in treatment naïve – those who have not received prior antiviral therapy […]

Fear of appearing promiscuous keeps women from using HIV-prevention drugs

Fear of appearing promiscuous keeps women from using HIV-prevention drugs

Fear of others thinking they’re promiscuous, or that they’re already infected with HIV, is a barrier to many women who might benefit from pills that help prevent the infection, a US study suggests. About 200,000 US women are thought to be strong candidates for HIV pre-exposure prophylaxis, or PrEP, but only about 50,000 are using […]

GSK's two-drug HIV treatment meets main goal in late stage studies

GSK's two-drug HIV treatment meets main goal in late stage studies

(Reuters) – GlaxoSmithKline’s two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field. FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, […]

GlaxoSmithKline's new HIV dual-drug regimen meets phase 3 goal, but analysts want more

GlaxoSmithKline's new HIV dual-drug regimen meets phase 3 goal, but analysts want more

GlaxoSmithKline’s ViiV Healthcare already has Juluca, the first complete two-drug HIV therapy, for patients who are virally suppressed. Now, it has new data to back its dual-drug expansion into treatment-naïve patients, but analysts want to see more data before giving their definite thumbs-up. In two phase 3 studies on altogether about 1,400 people living with […]

Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV

Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV

GlaxoSmithKline (GSK) popped to an 11-month high Thursday after its two-drug HIV treatment proved non-inferior to a three-drug regimen using medicine from Gilead Sciences (GILD). X On the stock market today, Glaxo shares jumped 1.9% to close at 41.94. Glaxo stock is forming a cup base with a buy point at 44.63. Gilead shares lifted […]

Babies who dodge HIV may not be unscathed

Babies who dodge HIV may not be unscathed

Exposure to the virus, the mother’s microbiome, and drugs each could cause harm. Up to half of babies born to HIV-infected mothers become infected themselves either in utero, during labor, or through breastfeeding, unless the mothers and babies are treated with antiretroviral (ARV) drugs. But several studies suggest an additional burden for the many children […]